Last $266.54 USD
Change Today -6.71 / -2.46%
Volume 2.7M
ACT On Other Exchanges
Symbol
Exchange
Berlin
New York
Mexico
As of 8:04 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

actavis plc (ACT) Snapshot

Open
$271.22
Previous Close
$273.25
Day High
$273.03
Day Low
$266.18
52 Week High
01/26/15 - $285.09
52 Week Low
02/5/14 - $180.70
Market Cap
70.9B
Average Volume 10 Days
2.6M
EPS TTM
$5.11
Shares Outstanding
266.1M
EX-Date
--
P/E TM
52.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTAVIS PLC (ACT)

actavis plc (ACT) Details

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment provides generic, branded generic, and over-the-counter (OTC) pharmaceutical products. This segment sells generic prescription products primarily under the Watson Laboratories, Watson Pharma, and Actavis Pharma labels; and OTC generic products under private label. The Actavis Specialty Brands segment offers patent-protected products and trademarked off-patent products, which are marketed as branded pharmaceutical products to physicians, specifically urologists, obstetricians, dermatologists, gastroenterologists, and gynecologists. The Anda Distribution segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables, and OTC medicines to independent pharmacies, and to alternate care providers comprising hospitals, nursing homes, and mail order pharmacies, as well as to pharmacy chains, physicians’ offices, and buying groups. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, urology, gastroenterology, and dermatology therapeutic categories. The company has a collaboration agreement with Amgen, Inc. for the development and commercialization of various oncology antibody biosimilar medicines; and a collaboration agreement with Hanmi Pharm. Co. Ltd. to develop Hyalrheuma, a hyaluronic acid injection for arthritis pain treatment. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.

19,200 Employees
Last Reported Date: 12/5/14
Founded in 1983

actavis plc (ACT) Top Compensated Officers

Executive Chairman
Total Annual Compensation: $2.6M
Chief Operating Officer
Total Annual Compensation: $639.5K
Compensation as of Fiscal Year 2013.

actavis plc (ACT) Key Developments

Gedeon Richter Plc. and Actavis plc Announces Positive Phase III Results for Cariprazine in the Prevention of Relapse in Patients with Schizophrenia

Gedeon Richter Plc. and Actavis plc announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. There were 101 patients randomized to cariprazine 3 to 9 mg per day and 99 randomized to placebo. The primary efficacy measure was time to first relapse during the double-blind period. There were 25 relapses (24.8%) in the cariprazine group versus 47 relapses (47.5%) in the placebo group. Treatment with cariprazine was associated with a 55% reduction in risk of relapse versus placebo (hazard ratio 0.45, 95% CI [0.28, 0.73] p=0.0010). This 97 week study was a multi-national, multi-center, randomized, double-blind, placebo-controlled clinical trial in adult patients with schizophrenia. The study included a 20-week open-label phase where patients with schizophrenia were treated with cariprazine 3, 6 or 9 mg per day. Patients who responded and met the stabilization criteria during the open-label period were then randomized to continue their cariprazine dose (3, 6 or 9 mg per day) or switched to placebo for up to 72 weeks or until a relapse occurred. The primary endpoint was time to first symptom relapse during the double blind phase.

Actavis Launches U.S. Generic Specialty Injectable Portfolio

Actavis plc announced the launch of a portfolio of generic specialty injectable medications to be marketed to hospitals across the United States. Actavis will immediately begin marketing approximately 20 injectable products across a number of therapeutic categories in the U.S. The Company will be a leader in Oncology, with nearly a dozen marketed products including generic versions of Gemzar, Taxotere, Campostar and Zometa. Actavis also has an specialty injectable pipeline, with approximately 20 new filings under review at the U.S. Food and Drug Administration (FDA), as well as more than 50 additional projects currently in development. Many of Actavis' generic specialty injectable products were previously marketed in the U.S. by Sagent Pharmaceuticals Inc. under a manufacturing and supply agreement originally signed by the companies in 2010. Actavis regained U.S. marketing rights to the products following the expiration of the Sagent agreement on December 31, 2014.

Actavis plc Announces Senior Management Changes

Actavis plc has announced senior management changes and named Brent Saunders to lead as CEO and president and a member of the board of directors. The planned senior management team is to lead the global pharmaceutical company following the successful close of the acquisition of Allergan Inc., anticipated in the second quarter of 2015. Paul Bisaro will remain Executive Chairman of the Board of Directors. Mr. Saunders will lead an expanded senior management team comprised of leaders from both Actavis and Allergan, designed to further enhance the Company's position as the fastest growing and most dynamic growth pharmaceutical company in global healthcare. The company announced that following the close Douglas Ingram, President, Allergan, will continue as a Special Advisor to me. The combined company will benefit from Doug's experience and expertise as it unites the two businesses, and help ensure that it integrates the two companies while recognizing and capitalizing on Allergan's unique product portfolio and market leadership positions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACT:US $266.54 USD -6.71

ACT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.76 USD -0.50
Allergan Inc/United States $219.26 USD -3.13
Astellas Pharma Inc ¥1,830 JPY +6.50
Eli Lilly & Co $72.00 USD -0.11
Teva Pharmaceutical Industries Ltd $56.86 USD -0.70
View Industry Companies
 

Industry Analysis

ACT

Industry Average

Valuation ACT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.1x
Price/Book 2.5x
Price/Cash Flow 68.4x
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTAVIS PLC, please visit www.actavis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.